162045-53-6

Basic information

• Product Name: tert-Butyl 4-(2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-1-carboxylate
• Synonyms: tert-Butyl 4-(2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-1-carboxylate;tert-butyl 4-(2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)piperidine-1-carboxylate;tert-Butyl 4-(2-oxobenzo[d]oxazol-3(2H)
• CAS NO: 162045-53-6
• Molecular Formula: C₁₇H₂₂N₂O₄
• Molecular Weight: 318.371
• Mol File: 162045-53-6.mol

Chemical Properties

• Boiling Point: 435.6°C at 760 mmHg
• Flash Point: 217.244°C
• Appearance: /
• Density: 1.246g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.571
• CAS DataBase Reference: tert-Butyl 4-(2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 4-(2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-1-carboxylate(162045-53-6)
• EPA Substance Registry System: tert-Butyl 4-(2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-1-carboxylate(162045-53-6)

Safety Data

• Hazardous Substances Data: 162045-53-6(Hazardous Substances Data)

Usage

Uses

Used in Scientific Research:
Tert-Butyl 4-(2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-1-carboxylate is utilized as a research tool for studying biological systems due to its distinctive chemical structure and properties.
Used in Drug Development:
In the pharmaceutical industry, this compound serves as a precursor or intermediate in the synthesis of new drugs, leveraging its potential biological activity for therapeutic applications.
Used in Medicinal Chemistry:
Tert-Butyl 4-(2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-1-carboxylate is applied as a component in the design and development of bioactive compounds, contributing to the advancement of medicinal agents with specific pharmacological effects.
While the provided materials do not specify particular applications in different industries, the compound's uses in scientific research, drug development, and medicinal chemistry are inferred based on its properties and common practices in these fields.

InChI:InChI=1/C17H22N2O4/c1-17(2,3)23-15(20)18-10-8-12(9-11-18)19-13-6-4-5-7-14(13)22-16(19)21/h4-7,12H,8-11H2,1-3H3

Upstream product

• 32315-10-9 bis(trichloromethyl) carbonate 
• 162045-48-9 1-(tert-butoxycarbonyl)-4-[(2-hydroxyphenyl)amino]piperidine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 95-55-6 2-amino-phenol 
• 59-49-4 2-Benzoxazolinone 
• 1972-28-7 diethylazodicarboxylate 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 215878-20-9 4-[2(3H)-oxobenzoxazol-3-yl]piperidine 
• 173842-04-1 5-Chloro-1,1-dioxido-2-(4-(4-(2-oxo-3-benzoxazolinyl)-piperidin-1-yl)-butyl)-1,2-benzisothiazol-3(2H)-one 

Relevant articles and documents

Effects of Pimozide Derivatives on pSTAT5 in K562 Cells

STAT5 is a transcription factor, a member of the STAT family of signaling proteins. STAT5 is involved in many types of cancer, including chronic myelogenous leukemia (CML), in which this protein is found constitutively activated as a consequence of BCR-ABL expression. The neuroleptic drug pimozide was recently reported to act as an inhibitor of STAT5 phosphorylation and is capable of inducing apoptosis in CML cells in vitro. Our research group has synthesized simple derivatives of pimozide with cytotoxic activity and that are able to decrease the levels of phosphorylated STAT5. In this work we continued the search for novel STAT5 inhibitors, synthesizing compounds in which the benzoimidazolinone ring of pimozide is either maintained or modified, in order to obtain further structure–activity relationship information for this class of STAT5 inhibitors. Two compounds of the series showed potent cytotoxic activity against BCR-ABL-positive and pSTAT5-overexpressing K562 cells and were able to markedly decrease the levels of phosphorylated STAT5.

Piperidine amides as 11β-hydroxysteroid dehydrogenase type 1 inhibitors

A series of piperidine amide inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) were identified via modifications of the HTS hit compound 1. The synthesis, in vitro biological evaluation, and structure-activity relationship of these co

Method for treating allergies using substituted pyrazoles

A method for treating an allergic condition, including an atopic allergic condition, using substituted pyrazoles.

P2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases

The invention provides piperidine compounds of general formula (I) in which A, B, X, Y, Z, R, R1 and R2 are as defined in the specification, their use as medicaments, compositions containing them and processes for their for their preparation.

Design and synthesis of N-alkylated saccharins as selective α-1a adrenergic receptor antagonists

Benign prostatic hyperplasia can be managed pharmacologically with α-1 adrenergic receptor antagonists. Agents that demonstrate selectivity for the α-la receptor subtype may offer advantages in clinical applications with respect to hypotensive side effect